Pipeline

Transcenta has established a pipeline of over ten innovative molecules in oncology, bone disorders and nephrology. Most of these are discovered and developed in house and some are acquired through in-licensing.

Program Target Indication	Pre-clinical IND Filing Ph I Ph II Ph III NDA/BLA Filing	Territory
MSB2311 PD-L1 Solid Tumors	MSB2311 - PD-L1 - Solid Tumors Territory：Global	Global
TST001 Claudin 18.2 Solid Tumors	TST001 - Claudin 18.2 - Solid Tumors Territory：Global	Global
MSB0254 VEGFR2 Solid Tumors	MSB0254 - VEGFR2 - Solid Tumors Territory：Global	Global
JCT205 DR5 Solid Tumors	JCT205 - DR5 - Solid Tumors Territory：Greater China(In-licensed from InhibRx)	Greater China(In-licensed from InhibRx)
TST005 Undisclosed Solid Tumors	TST005 - Undisclosed - Solid Tumors Territory：Global	Global
TST002 Sclerostin Osteoporosis	TST002 - Sclerostin - Osteoporosis Territory：Greater China (In-licensed from Eli Lilly)	Greater China (In-licensed from Eli Lilly)
TST004 Undisclosed Nephrology	TST004 - Undisclosed - Nephrology Territory：Global	Global
TST003 Undisclosed Solid Tumors	TST003 - Undisclosed - Solid Tumors Territory：Global	Global
TST006 Undisclosed Oncology	TST006 - Undisclosed - Oncology Territory：Global	Global
TST007 Undisclosed Oncology	TST007 - Undisclosed - Oncology Territory：Global	Global
TST008 Undisclosed Nephrology	TST008 - Undisclosed - Nephrology Territory：Global	Global

Non-oncology

Oncology

Program:
MSB2311
Target:
PD-L1
Indication:
Solid Tumors

brief introduction:

Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting.